Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...

GSK may not have been surprised its anti-TIM-3 drug couldn’t secure a phase 3 win based on how its pharma peers have struggled. (iStock / Getty Images Plus) GSK’s cobolimab has become the latest ...

BioCardia said that CardiAMP was associated with “trends” toward reduced ventricular tachyarrhythmias and enhanced heart function as measured by left ventricular ejection fraction. (Natalija ...

Oliguric renal failure is a phase of acute renal failure (ARF), also known as acute kidney injury (AKI), in which a person’s urine output is very low. ARF is a sudden decline in kidney functioning.

Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...

– PDE9 inhibitor, CRD-740, demonstrated favorable safety profile and achieved statistical significance for the trial’s primary endpoint, median increase in plasma cyclic guanosine monophosphate (cGMP) ...